Enanta Pharmaceuticals, Inc.
330 articles about Enanta Pharmaceuticals, Inc.
-
Enanta Pharmaceuticals, Inc. Announces New Data on ABT-450 Regimens to be Presented at The Liver Meeting American Association for Study of Liver Diseases
10/1/2013
-
Enanta Pharmaceuticals, Inc. Announces National Institute of Allergy And Infectious Diseases (NIAID) Will Fund Further Development of a Novel Bicyclolide
9/3/2013
-
Enanta Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
8/29/2013
-
Enanta Pharmaceuticals, Inc. Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended June 30, 2013
8/12/2013
-
Enanta Pharmaceuticals, Inc. Celebrates Their Recent IPO and Recognizes World Hepatitis Day by Ringing the NASDAQ Stock Market Opening Bell
7/25/2013
-
Enanta Pharmaceuticals, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
7/1/2013
-
Enanta Pharmaceuticals, Inc. Added to the Russell 3000® and Russell 2000® Indexes
7/1/2013
-
Enanta Pharmaceuticals, Inc. to Present at the Wells Fargo Securities 2013 Healthcare Conference
6/14/2013
-
Enanta Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
5/28/2013
-
Enanta Pharmaceuticals, Inc. Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013
5/8/2013
-
Enanta Pharmaceuticals, Inc. Release: Breakthrough Therapy Designation From the FDA Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450
5/6/2013
-
Enanta Pharmaceuticals, Inc. Announces New Data From Phase 2b Interferon-Free Combination Studies With Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
4/23/2013
-
Enanta Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
3/27/2013
-
Enanta Pharmaceuticals, Inc. Raises $56 Million in IPO
3/21/2013
-
TetraPhase Pharmaceuticals, Enanta Pharmaceuticals, Inc. Prepare for IPOs
3/19/2013
-
Enanta Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering
11/7/2012
-
Enanta Pharmaceuticals, Inc.'s Lead Hep. C Compound ABT-450 Advances Into a Phase 3 Trial With Abbott Laboratories
10/17/2012
-
Enanta Pharmaceuticals, Inc. Announces Positive Phase 2 Results From Interferon-Free Combination Studies With ABT-450 for Hepatitis C Treatment to be Presented at EASL
4/4/2012
-
Enanta Pharmaceuticals, Inc. Strikes Hep C Drug Deal With Novartis AG Worth Up to $440 Million
2/22/2012
-
Enanta Pharmaceuticals, Inc. Awarded up to $42.7 Million National Institute of Allergy And Infectious Diseases (NIAID) Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic
10/13/2011